GI Pancreatic - Metastatic

Localized

NeoAdjuvant

Adjuvant

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

**IRB# 19211**
A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma

**IRB# 21614**
NeoOptimize: An Open-Label, Phase II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A Neoadjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.

**IRB# 17751**
Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

**IRB#15588**
Serial Measurements of Molecular and Architectural Responses to Therapy

**IRB# 17094**
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

**IRB#23124**
A Phase 1b/2 Randomized Study of AVB-S6-500 plus Nab-paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma

**IRB# 23316**
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors

**IRB# 22141**
A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination with Cobimetinib in locally advanced or Metastatic Pancreatic Cancer

**IRB# 17094**
A Phase Ib/I, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

**IRB#23124**
A Phase 1b/I, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

**IRB# 20679**
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

**Cross-Disease Trials:**

**IRB #20679**
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

**IRB #23124**
A Phase 1b/I, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

**IRB #22141**
A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination with Cobimetinib in locally advanced or Metastatic Pancreatic Cancer

**KEY**
- Open to Enrollment
- In Development
- Enrollment on Hold

02 MAY 2022

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result